
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9272665/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 2022, 12, 108-133.	7.7	165
2	Essential medicines list in national cancer control plans: a secondary analysis from a global study. Lancet Oncology, The, 2022, 23, e144-154.	5.1	9
3	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). Journal of Thoracic Oncology. 2021. 16. 278-288.	0.5	82
4	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study Journal of Clinical Oncology, 2021, 39, 2533-2533.	0.8	0
5	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2021, 16, 990-1002.	0.5	37
6	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open, 2021, 11, e049232.	0.8	10
7	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. Journal of Thoracic Oncology, 2020, 15, 416-425.	0.5	17
8	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage l–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Modern Pathology, 2020, 33, 792-801.	2.9	28
9	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of Thoracic Oncology. 2020. 15. 1647-1656.	0.5	34
10	EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open, 2020, 5, e000611.	2.0	10
11	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer, 2019, 134, 127-140.	0.9	156
12	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology, 2019, 14, 1086-1094.	0.5	99
13	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial. Lung Cancer, 2019, 133, 83-87.	0.9	113
14	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer, 2019, 131, 95-103.	0.9	40
15	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology, 2019, 37, 336-349.	0.8	101
16	Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. Breast Care, 2019, 14, 344-353.	0.8	125
17	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of Translational Medicine, 2019, 17, 391.	1.8	42
18	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 2019, 30, 161-165.	0.6	60

#	Article	IF	CITATIONS
19	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine, 2018, 10, .	5.8	326
20	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	0.5	66
21	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical Cancer Research, 2018, 24, 3079-3086.	3.2	15
22	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. ESMO Open, 2018, 3, e000422.	2.0	50
23	Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab. JCO Precision Oncology, 2018, 2, 1-12.	1.5	5
24	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. Journal of Thoracic Oncology, 2018, 13, 1851-1863.	0.5	6
25	Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients. Annals of Oncology, 2018, 29, x40.	0.6	29
26	Report on the status of women occupying leadership roles in oncology. ESMO Open, 2018, 3, e000423.	2.0	35
27	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial Journal of Clinical Oncology, 2018, 36, 8510-8510.	0.8	20
28	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 435-444.	5.2	172
29	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified byÂVeriStrat Good versus VeriStrat Poor. The EuropeanÂThoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. Journal of Thoracic Oncology, 2017, 12, 752-762.	0.5	17
30	ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology, 2017, 28, 2340-2366.	0.6	451
31	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer, 2017, 111, 143-149.	0.9	57
32	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. ESMO Open, 2017, 2, e000216.	2.0	20
33	A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a <i>HER2</i> mutation: The ETOP NICHE trial Journal of Clinical Oncology, 2017, 35, 9070-9070.	0.8	21
34	Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort Journal of Clinical Oncology, 2017, 35, 8516-8516.	0.8	0
35	Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open, 2016, 1, e000055.	2.0	28
36	Selection of the primary end point in an observational cohort study. Journal of Epidemiology and Community Health, 2016, 70, 950-953.	2.0	2

#	Article	IF	CITATIONS
37	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology, 2016, 2, 1040.	3.4	73
38	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Annals of Oncology, 2016, 27, 1818-1828.	0.6	88
39	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget, 2016, 7, 21247-21258.	0.8	86
40	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372) Journal of Clinical Oncology, 2016, 34, TPS8571-TPS8571.	0.8	7
41	Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. , 2016, , .		0
42	Reply to D. Adkins et al. Journal of Clinical Oncology, 2015, 33, 1225-1226.	0.8	1
43	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	0.6	635
44	Abstract P5-18-01: TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial. , 2015, , .		0
45	Abstract P3-06-02: Exploratory analysis of single gene predictive biomarkers in TransHERA DASL cohort reveals that C8A mRNA expression is prognostic of outcome and predictive of benefit of trastuzumab. , 2015, , .		0
46	Combining Cetuximab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: Is More Better?. Journal of Clinical Oncology, 2014, 32, 2929-2931.	0.8	6
47	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 2014, 32, 2780-2787.	0.8	163
48	Informed Choice of Composite End Points in Cardiovascular Trials. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 170-178.	0.9	21
49	Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	0.5	31
50	Phase II Design With Sequential Testing of Hypotheses Within Each Stage. Journal of Biopharmaceutical Statistics, 2014, 24, 768-784.	0.4	0
51	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer, 2014, 14, 515.	1.1	26
52	In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. PLoS ONE, 2014, 9, e99131.	1.1	21
53	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer. 2013, 13, 163.	1.1	27
54	Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Annals of Oncology, 2013, 24, 1011-1017.	0.6	87

#	Article	IF	CITATIONS
55	Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel. PLoS ONE, 2012, 7, e37946.	1.1	54
56	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	1.1	48
57	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncology, The, 2011, 12, 236-244.	5.1	575
58	The MARS feasibility trial: conclusions not supported by data. Lancet Oncology, The, 2011, 12, 1093-1094.	5.1	121
59	Landmark Analysis at the 25-Year Landmark Point. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 363-371.	0.9	367
60	Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Research and Treatment, 2010, 119, 621-631.	1.1	74
61	Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer, 2010, 10, 45.	1.1	27
62	Correlation of molecular human leukocyte antigen typing and outcome in highâ€risk melanoma patients receiving adjuvant interferon. Cancer, 2010, 116, 4326-4333.	2.0	35
63	Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. Journal of Clinical Oncology, 2010, 28, 3422-3428.	0.8	228
64	Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. Clinical Cancer Research, 2010, 16, 2427-2434.	3.2	59
65	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. Journal of Translational Medicine, 2010, 8, 108.	1.8	25
66	Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Research, 2010, 12, R24.	2.2	70
67	Reply to S.S. Agarwala et al. Journal of Clinical Oncology, 2009, 27, e84-e84.	0.8	Ο
68	Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma. Journal of Clinical Oncology, 2009, 27, 939-944.	0.8	107
69	Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Annals of Oncology, 2009, 20, 49-55.	0.6	39
70	Reply to P. Mohr et al. Journal of Clinical Oncology, 2009, 27, e71-e71.	0.8	0
71	Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. Clinical Cancer Research, 2009, 15, 6454-6461.	3.2	97
72	Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. Journal of Clinical Oncology, 2009, 27, 2962-2969.	0.8	164

#	Article	IF	CITATIONS
73	A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 87-99.	1.1	74
74	Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research, 2009, 11, R35.	2.2	31
75	Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy. Anticancer Research, 2009, 29, 693-702.	0.5	9
76	Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. British Journal of Cancer, 2008, 99, 1775-1785.	2.9	56
77	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Annals of Oncology, 2008, 19, 853-860.	0.6	45
78	Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. Anticancer Research, 2008, 28, 2913-20.	0.5	9
79	Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. Oncology, 2007, 72, 388-396.	0.9	16
80	Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. International Journal of Cancer, 2007, 121, 486-494.	2.3	60
81	Pituitary-adrenal responses to human corticotropin-releasing hormone in critically ill patients. Intensive Care Medicine, 2007, 33, 454-459.	3.9	21
82	Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non–nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2006, 17, 1560-1567.	0.6	20
83	Prospective Assessment of Fatigue and Health Status in Greek Patients With Breast Cancer Undergoing Adjuvant Radiotherapy. Oncology Nursing Forum, 2006, 33, 603-610.	0.5	25
84	Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Annals of Oncology, 2006, 17, 1504-1511.	0.6	41
85	Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. New England Journal of Medicine, 2006, 354, 709-718.	13.9	593
86	Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2005, 16, 1762-1771.	0.6	95
87	Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2004, 15, 1517-1526.	0.6	63
88	Dysthymic Reactions of Women Undergoing Chorionic Villus Sampling for Prenatal Diagnosis of Hemoglobinopathies or Karyotyping. Fetal Diagnosis and Therapy, 2004, 19, 149-154.	0.6	5
89	A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Annals of Oncology, 2004, 15, 1250-1255.	0.6	27
90	Concomitant Radiochemotherapy vs Radiotherapy Alone in Patients with Head and Neck Cancer: A Hellenic Cooperative Oncology Group Phase III Study. Medical Oncology, 2004, 21, 095-108.	1.2	95

#	Article	IF	CITATIONS
91	Blood Leptin and Adiponectin as Possible Mediators of the Relation Between Fat Mass and BMD in Perimenopausal Women. Journal of Bone and Mineral Research, 2004, 19, 546-551.	3.1	170
92	The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome. Intensive Care Medicine, 2004, 30, 1216-1219.	3.9	44
93	Usefulness of Tumor Volumetry as a Prognostic Factor of Survival in Head and Neck Cancer. Strahlentherapie Und Onkologie, 2003, 179, 292-297.	1.0	47
94	8q24 Copy number gains and expression of the c-myc mRNA stabilizing proteinCRD-BP in primary breast carcinomas. International Journal of Cancer, 2003, 104, 54-59.	2.3	58
95	Ultrastructural Immunostaining of Infiltrating Ductal Breast Carcinomas with the Monoclonal Antibody H: A Comparative Study with Cytokeratin 8. Ultrastructural Pathology, 2003, 27, 393-407.	0.4	12
96	Association of Proinflammatory Molecules with Apoptotic Markers and Survival in Critically III Multiple Organ Dysfunction Patients. Biological Research for Nursing, 2003, 5, 129-141.	1.0	7
97	Ultrastructural Immunostaining of Infiltrating Ductal Breast Carcinomas with the Monoclonal Antibody H: A Comparative Study with Cytokeratin 8. Ultrastructural Pathology, 2003, 27, 393-407.	0.4	0
98	Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. Annals of the Rheumatic Diseases, 2002, 61, 398-404.	0.5	60
99	A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer, 2002, 94, 452-458.	2.0	64
100	Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology, 2001, 19, 2232-2239.	0.8	22
101	Lipid-associated sialoprotein in the cerebrospinal fluid. Cancer, 2001, 92, 856-862.	2.0	5
102	Melatonin response to clonidine administration in depression: indication of presynaptic α2-adrenoceptor dysfunction. Journal of Affective Disorders, 2001, 65, 307-313.	2.0	18
103	Dental and periodontal status of Sjögren's syndrome. Journal of Clinical Periodontology, 2000, 27, 231-235.	2.3	68
104	Clinical evolution, and morbidity and mortalityof primary Sjögren's syndrome. Seminars in Arthritis and Rheumatism, 2000, 29, 296-304.	1.6	433
105	Fluorouracil and Leucovorin with or without Interferon Alfa-2a as Adjuvant Treatment, in Patients with High-Risk Colon Cancer. Oncology, 2000, 58, 227-236.	0.9	16
106	Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Annals of the Rheumatic Diseases, 2000, 59, 359-367.	0.5	61
107	Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Acute Lung Injury. Circulation, 2000, 102, 2011-2018.	1.6	153
108	Determinants of Hospital Mortality After Coronary Artery Bypass Grafting. Chest, 1999, 115, 1598-1603.	0.4	113

OURANIA DAFNI

#	Article	IF	CITATIONS
109	Further Evidence That Routinely Reported Sexually Transmitted Diseases Presage the Evolution of the AIDS Epidemic. Epidemiology, 1999, 10, 788.	1.2	Ο
110	Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: A randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology, 1999, 10, 671-676.	0.6	39
111	Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1998, 338, 1345-1351.	13.9	343
112	Phrenic Nerve Dysfunction After Cardiac Operations. Chest, 1998, 113, 8-14.	0.4	109
113	Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic. Journal of Rheumatology, 1998, 25, 886-91.	1.0	16
114	Prevalence of Sjogren's syndrome in a closed rural community. Annals of the Rheumatic Diseases, 1997, 56, 521-525.	0.5	139
115	Routinely Reported Sexually Transmitted Diseases Presage the Evolution of the AIDS Epidemic. Epidemiology, 1997, 8, 449.	1.2	6
116	Analysis of myopathy in a placebo-controlled zidovudine trial. , 1997, 20, 382-385.		28
117	Effects of Low Energy Emission Therapy in Chronic Psychophysiological Insomnia. Sleep, 1996, 19, 327-336.	0.6	35
118	Electroencephalographic changes following low energy emission therapy. Annals of Biomedical Engineering, 1996, 24, 424-429.	1.3	17
119	Determinants of duration of ICU stay after coronary artery bypass graft surgery. British Journal of Anaesthesia, 1996, 77, 208-212.	1.5	44
120	Subjective and objective relaxation effects of low energy emission therapy. Stress and Health, 1994, 10, 5-13.	0.7	5
121	Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. Annals of Neurology, 1993, 33, 343-349.	2.8	262
122	Performance evaluation in multicenter clinical trials: Development of a model by the AIDS Clinical Trials Group. Contemporary Clinical Trials, 1993, 14, 523-537.	2.0	10
123	Modeling the Progression of HIV Infection. Journal of the American Statistical Association, 1991, 86, 569-577.	1.8	77
124	Modeling the Progression of HIV Infection. , 0, .		18

8